Quantcast

Latest Neuroprotection Stories

2010-11-15 21:24:38

Fisetin, a naturally occurring compound found in strawberries and other fruits and vegetables, slows the onset of motor problems and delays death in three models of Huntington's disease, according to researchers at the Salk Institute for Biological Studies. The study, published in the online edition of Human Molecular Genetics, sets the stage for further investigations into fisetin's neuroprotective properties in Huntington's and other neurodegenerative conditions. Huntington's disease (HD)...

2010-11-08 15:06:48

Research led by Dr. Nicolas Bazan, Boyd Professor, Villere Chair, and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center, has shown that Docosahexaenoic acid (DHA), a component of fish oil, is a powerful therapeutic agent that can protect brain tissue and promote recovery in an experimental model of acute ischemic stroke, even when treatment is delayed by up to five hours. These findings not only target a new stroke treatment approach, but also provide vital...

2010-09-20 22:20:23

A team of researchers, led by Scott Oakes, at the University of California, San Francisco, has identified a way to prevent symptom onset, weight loss, and paralysis and extend survival in a mouse model of amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig's disease), providing a new avenue of research for the development of therapeutics for ALS and other motor neuron diseases. ALS and other motor neuron diseases are neurological disorders that selectively affect nerve cells that...

2010-08-25 07:00:00

ROCKVILLE, Md., Aug. 25 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A...

2010-07-16 17:32:00

LOS ANGELES, July 16 /PRNewswire/ -- Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as...

2010-07-12 06:30:00

HONG KONG, July 12 /PRNewswire-FirstCall/ - AlphaRx, Inc. (OTCBB: ALRX) announced positive preclinical results of GAI-122 injectable nanoemulsion, a Mitochondria-targeted neuroprotective drug candidate being developed for the treatment of Acute Ischemic Stroke. The results will be delivered as a podium presentation during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, OregonJuly 10 - 14, 2010. On Wednesday, July 14, 2010, Dr. Joseph Schwarz, Chief...

cf43dd65b7da643b67dcce48e523dea9
2010-07-08 14:40:07

NIH grantees eye neuroprotective mechanism for Alzheimer's Scientists have discovered a compound that restores the capacity to form new memories in aging rats, likely by improving the survival of newborn neurons in the brain's memory hub. The research, funded in part by the National Institutes of Health, has turned up clues to a neuroprotective mechanism that could lead to a treatment for Alzheimer's disease. "This neuroprotective compound, called P7C3, holds special promise because of its...

2010-07-01 12:02:00

RICHMOND, Calif., July 1 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has been awarded a second round of funding by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support studies in non-human primates for the development of a ZFP Therapeutic(TM) to treat Parkinson's disease (PD). The $900,000 award will be paid over a period of two years. Sangamo has developed zinc finger DNA-binding protein transcription factors (ZFP TFs)...

2010-06-28 07:30:00

FREMONT, Calif., June 28 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal. Prof. Di Polo's recent study in a rat model of glaucoma shows that QPI-1007, when given in two intravitreal...

2010-06-24 09:00:00

FREMONT, Calif., June 24 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that two of its siRNA drug candidates were featured in the following two presentations at the Glaucoma & Retinopathies 2010 conference, which was held June 21-22, 2010 in London, UK: "QPI-1007, an ocular neuroprotective siRNA for ameliorating RGC (retinal ganglion cell) loss," presented by Elena Feinstein, Chief Scientific...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.